세계의 HIV 진단 및 치료제 시장

Highlights:

The global market for HIV diagnostics and therapeutics is expected to increase from $30.4 billion in 2023 to $39.3 billion by the end of 2028, with compound annual growth rate (CAGR) of 5.3% during the forecast period of 2023-2028.

Single-tablet regimen FDC market for HIV diagnostics and therapeutics is expected to increase from $11.3 billion in 2023 to $14.9 billion by the end of 2028, at a CAGR of 5.8 during the forecast period of 2023-2028.

Nucleoside reverse transcriptase inhibitors market for HIV diagnostics and therapeutics is expected to increase from $8.9 billion in 2023 to $11.0 billion by the end of 2028, at a CAGR of 4.4% during the forecast period of 2023-2028.

Report Scope:

This report organizes information from diverse sources into sections such as an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements, and patents. The scope of this report includes an overview of the global market scenario for the diagnosis and treatment of HIV, with base year data from 2022, estimations for 2023 and forecasts for 2028 that are derived using projections of CAGR during the forecast period. Market value data is provided at global, regional, and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class. It discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests, and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

A detailed analysis illustrating market dynamics and market structure is incorporated into the report. A Porter's Five Forces analysis and the supply and distribution chain are discussed in detail to provide an in-depth understanding of this market. The report covers the current regulations and guidelines for diagnostics and therapeutics for HIV, and it provides a survey of the top market players, detailing their business operations, segment focus, revenue, and strategy analysis. The report also features a market share analysis of these leading players, including information about product launches and pipeline products.

In terms of geography, the report analyzes the market across the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Key countries like the U.S., Canada, Mexico, Germany, France, UK, Italy, China, India and Japan are given special focus due to the high concentration of HIV diagnostics and therapeutics manufacturing companies and contract manufacturing organizations located in these areas.

The base year for the market data in this report is 2022, historical data is provided for 2020 and forecast data is given for 2028. Historical, base year and forecast data are provided for each market segment of the report.

Report Includes:

• 27 data tables and 41 additional tables
• An overview of the global markets for diagnostics and therapeutics for HIV
• An estimate of the market's size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Quantification of the market potential of diagnostics and therapeutics for HIV by drug category, diagnostic test type, and region
• Coverage of HIV timeline and milestones, HIV life cycle, its treatment and mechanism of action, and description of HIV prophylaxis
• Evaluation of market dynamics such as drivers and restraints, current industry trends and patterns, and an assessment of the cost implications for treatments in many countries
• Information on regional awareness programs, WHO initiatives and development of novel therapies, and discussion on rising comorbidities in HIV patients and social stigma associated with STDs
• Coverage of ongoing research and predictions of the market's future direction
• Insights into the regulatory scenario for the U.S., Europe and Japan, to provide an overview of the regulations for new drug launches and diagnostic kits
• Descriptions of the competitive landscape, product mapping, the strategic initiatives of the leading companies, including their R&D activities
• Profiles of the key companies, including Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories Inc., and Danaher Corp.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Update?
• Scope of Report
• Information Sources and Methodology
• Secondary Research
• Primary Research
• Research Methodology
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Overview
• Market Outlook

Chapter 3 Market and Technology Background

• Overview of Human Immunodeficiency Virus (HIV)
• Report Overview
• Disease Prognosis
• Symptoms
• Treatments
• HIV Timeline and Milestones
• HIV Life Cycle: Treatment and Mechanism of Action
• HIV Prophylaxis
• Pre-exposure Prophylaxis (PrEP)
• Post-exposure Prophylaxis (PEP)
• Drug Resistance
• Medication Adherence
• WHO Initiatives

Chapter 4 Global Industry Trends

• Trends in Global HIV Transmission
• Regional Awareness Programs
• Development of Novel Therapies
• Public-Private Partnerships
• Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
• Global Programs to Counter HIV
• Preventing Transmission from Mother to Child
• Challenges
• Underestimating the Risk of Contracting the Disease
• Social Stigma Associated with STDs
• High Cost of Treatment

Chapter 5 Market Breakdown by HIV Therapeutic

• Global Market Forecast for HIV Therapeutics
• Regional Markets for HIV Therapeutics
• North America
• Market Analysis and Forecast
• Epidemiology
• HIV Testing and Recommendations
• Regulation of the North American Market for HIV Therapeutics
• European Market for HIV Therapeutics
• Market Analysis and Forecast
• Epidemiology
• HIV Testing and Recommendations
• Regulations Impacting the European HIV Market
• Asia-Pacific Market for HIV Therapeutics
• Southeast Asian Regions
• Western Pacific Regions
• Prevention and Screening Programs
• Regulation of the Asia-Pacific HIV Market
• Market Impact of Generic Manufacturers
• Market Analysis and Forecast
• Rest of the World (RoW) Market for HIV Therapeutics
• African Region
• Global Investments in the HIV Market

Chapter 6 HIV Market by ARV Drug Category

• Overview
• Timeline of Therapies
• First-Line Treatment Regimen
• Second-Line Treatment Regimen
• Third-Line/Salvage Treatment Regimen
• Market Overview by Drug Category
• Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
• Protease Inhibitors (PIs)
• Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
• Integrase Strand Transfer Inhibitors (INSTI)
• Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
• Entry Inhibitors

Chapter 7 Emerging Technologies

• Overview
• Molecular Diagnostics
• Next-Generation Sequencing (NGS)
• Point-of-Care Testing
• Artificial Intelligence (AI)
• Other Emerging Techniques

Chapter 8 Evaluation of Market for HIV Diagnostics

• Market for HIV Diagnostics by Test Type
• Evolution of HIV Tests
• Antigen- and Antibody-Based Tests
• Future Perspective
• CD4 Testing
• Viral Load Testing
• HIV Diagnostic Product Profiles by Test Type
• CD4 Testing Products
• Viral Load Testing Products

Chapter 9 Patents

• Overview

Chapter 10 Competitive Landscape

• Mergers, Acquisitions and Collaborations

Chapter 11 Company Profiles

• ABBOTT
• ASTRAZENECA
• B. BRAUN SE
• BECTON, DICKINSON AND COMPANY
• BIOCON
• BIO-RAD LABORATORIES INC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• DANAHER CORP.
• DEXCOM INC.
• INSULET CORP.
• JOHNSON & JOHNSON SERVICES INC.
• LIFESCAN IP HOLDINGS LLC
• LILLY
• MEDTRONIC
• MERCK & CO. INC.
• NOVA BIOMEDICAL
• NOVARTIS AG
• NOVO NORDISK A/S
• QIAGEN N.V.
• ROCHE (F. HOFFMANN-LA ROCHE LTD.)
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• THERMO FISHER SCIENTIFIC INC.
• YPSOMED AG